DGS Capital Management LLC Has $413,000 Holdings in InMode Ltd. (NASDAQ:INMD)

DGS Capital Management LLC boosted its position in shares of InMode Ltd. (NASDAQ:INMD) by 129.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 24,704 shares of the healthcare company’s stock after purchasing an additional 13,948 shares during the period. DGS Capital Management LLC’s holdings in InMode were worth $413,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its position in shares of InMode by 314.7% during the 3rd quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company’s stock worth $60,000 after acquiring an additional 2,694 shares in the last quarter. Quarry LP lifted its stake in InMode by 154.3% during the third quarter. Quarry LP now owns 3,781 shares of the healthcare company’s stock worth $64,000 after purchasing an additional 2,294 shares during the last quarter. National Bank of Canada FI boosted its holdings in shares of InMode by 6.2% in the 3rd quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company’s stock valued at $169,000 after purchasing an additional 579 shares in the last quarter. GW Henssler & Associates Ltd. acquired a new stake in shares of InMode in the 3rd quarter valued at $177,000. Finally, Orion Portfolio Solutions LLC bought a new position in shares of InMode in the 3rd quarter valued at $194,000. 68.04% of the stock is owned by institutional investors.

InMode Trading Down 0.1 %

Shares of INMD stock opened at $17.25 on Friday. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of 9.32 and a beta of 2.12. The business’s 50-day moving average price is $17.64 and its 200-day moving average price is $17.24. InMode Ltd. has a 12 month low of $14.87 and a 12 month high of $26.80.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on INMD shares. Needham & Company LLC restated a “hold” rating on shares of InMode in a research report on Thursday, October 31st. BTIG Research initiated coverage on shares of InMode in a report on Thursday, October 17th. They issued a “buy” rating and a $25.00 target price for the company. Finally, Barclays decreased their price target on shares of InMode from $27.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 9th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $22.40.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.